Sunobinop

Sunobinop
Clinical data
Other names	IMB-115
Drug class	Nociceptin receptor agonist
Identifiers
	IUPAC name 4-[(1R,5S)-9-[(1S,5S)-3-bicyclo[3.3.1]nonanyl]-9-azabicyclo[3.3.1]nonan-3-yl]-3-oxoquinoxaline-2-carboxylic acid;
CAS Number	1126793-40-5;
PubChem CID	155801560;
ChemSpider	34950269;
UNII	I1X86U5474;
ChEMBL	ChEMBL4650344;
Chemical and physical data
Formula	C26H33N3O3
Molar mass	435.568 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)C1=NC=2C=CC=CC2N(C1=O)C3CC4N(C(CCC4)C3)C5CC6CCCC(C5)C6;
	InChI InChI=1S/C26H33N3O3/c30-25-24(26(31)32)27-22-9-1-2-10-23(22)29(25)21-14-18-7-4-8-19(15-21)28(18)20-12-16-5-3-6-17(11-16)13-20/h1-2,9-10,16-21H,3-8,11-15H2,(H,31,32)/t16-,17-,18-,19+,21?/m0/s1; Key:COTYYZPYDJKKIS-MCXOOUIESA-N;

Sunobinop (developmental code names V117957; IMB-115) is a high affinity small molecule nociceptin receptor partial agonist.

As of February 2024, it is under clinical investigation for the treatment of insomnia, alcohol use disorder, interstitial cystitis, and overactive bladder syndrome. It was previously also under investigation for the treatment of fibromyalgia.